CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 19-898/S016

Trade Name: Pravacol Tablets

Generic Name: pravastatin sodium

Sponsor: Bristol Myers Squibb Company

Approval Date: April 4, 1996

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-898/S016

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-898/S016

APPROVAL LETTER

NDA 19-898/S-016

APR - 4 1996

Bristol-Myers Squibb Company
Attention: John F. Bedard
Vice President, Worldwide Regulatory Affairs
P.O. Box 4000
Princeton, New Jersey 08543-4000

Dear Mr. Bedard:

Please refer to your November 27, 1995, supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pravacol®(pravastatin sodium) Tablets.

The supplemental application provides for a reprocessing method at the Mayaguez, Puerto Rico, facility for reduced-mass pravastatin sodium tablets which fail physical appearance specifications.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Ms. Julie Rhee, Consumer Safety Officer, at (301) 443-3510.

Sincerely yours,

Stephen K. Moore 4/4/96

Stephen K. Moore, Ph.D.
Acting Supervisory Chemist II
Division of New Drug Chemistry, II
Office of New Drug Chemistry, OPS,
at Division of Metabolism and
Endocrine Drug Products (HFD-510)
Center for Drug Evaluation and Research

cc:
Original NDA 19-898
HFD-510/Div. Files
HFD-510/Moore/Berlin
HFD-511/J.Rhee
HFD-80
DISTRICT OFFICE
HFD-232

drafted: jr/March 29, 1996/ c:wpfiles/supplement/19898s16.cap
r/d Initials:Galliers 4-3-96/Berlin 4-3-96/Moore 4-4-96
final: JRhee 4-4-96 jr 4-4-96

APPROVAL (S-016)

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 19-898/S016

CHEMISTRY REVIEW(S)

ORIGINAL

MAR 26 1996

CHEMISTS REVIEW	1. ORGANIZATION	2. NDA NUMBER
	DMEDP II, HFD-510	19-898
3. NAME AND ADDRESS OF APPLICANT		4. SUPPLEMENT NUMBER, DATE
Bristol-Myers Squibb Company P.O. Box 4000 Princeton, NJ 08543-4000		SCS-016, 11-27-95
5. NAME OF THE DRUG	6. PROPRIETARY NAME	7. AMENDMENTS, REPORT, DATE
Pravastatin Sodium	Pravachol	
8. SUPPLEMENT PROVIDES FOR		
A reprocessing method for reduced-mass pravastatin sodium tablets which fail physical appearance specifications (Mayaguez P.R. facility only).		
9. PHARMACOLOGICAL CATEGORY	10. HOW DISPENSED	11. RELATED IND, NDA, DMF
Antihypercholestremic	RX	
12. DOSAGE FORM	13. POTENCY	
Tablets, oral administration	10,20,40 mg.	
14. CHEMICAL NAME AND STRUCTURE		
See Chemistry Review #1		
15. COMMENTS		
The sponsor has provided adequate descriptions of the reprocessing operations. Copies of master and completed batch records for each strength were provided. Appropriate supporting data has been provided in terms of comparative dissolution data between original and reprocessed tablets, and certificates of analysis for reprocessed batches. Data were provided for reprocessed tablets made from representing a "worst case scenario." These tablets met specifications and demonstrated equivalency with data for virgin tablets. Stability data (at least 6 months) were provided for two (20 and 40 mg) strengths of the reprocessed tablets. The sponsor included stability protocols, rational for expiration dating, and a commitment to palce new batches of the reprocessed tablets on stability schedules. (continued on next page)		
16. CONCLUSION AND RECOMMENDATION		
The information provided in this supplement is adequate. Issue an approval letter.		
17. NAME	18. REVIEWERS SIGNATURE	19. DATE COMPLETED
WILLIAM K. BERLIN		3-26-96
DISTRIBUTION: ORIGINAL JACKET	CSO	REVIEWER DIVISION FILE

Stephen Moore
3/26/96

Comments Continued:

The sponsor's request to waive the environmental assessment is granted based on their arguements that the drug product will not be administered in larger amounts or for longer durations nor for different indications as a result of this supplement. Further, the reprocessing opperation will limit the environmental burden of disposal of unusable material, arguing in favor of approval of this supplement.

2 Page(s) Withheld

✓ § 552(b)(4) Trade Secret / Confidential

_____ § 552(b)(4) Draft Labeling

_____ § 552(b)(5) Deliberative Process

Withheld Track Number: Chemistry-19-898
S016

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 19-898/S016

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

Date DEC -5 1995

NDA No. 19-898

BRISTOL-MYERS SQUIBB COMPANY
P.O. Box 4000
Princeton, New Jersey 08543-4000

Attention: John F. Bedard, Vice President, WWRA

Dear Sir/Madam:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: PRAVACHOL

NDA Number: 19-898

Supplement Number: S-016

Date of Supplement: November 27, 1995

Date of Receipt: November 29, 1995

Unless we find the application not acceptable for filing, the filing date will be 60 days from the receipt date above.

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Attention: Document Control Room 14B-03
5600 Fishers Lane, HFD-510
Rockville, MD 20857

Sincerely yours,

Supervisory Consumer Safety Officer
Division of Metabolism and Endocrine Drug Products
Center for Drug Evaluation and Research

NDA SUPPLEMENT ORIGINAL

NDA NO. 19-898 SER. NO.

S-016

Bristol-Myers Squibb
Pharmaceutical Research Institute

P.O. Box 4000 Princeton, NJ 08543-4000
609 252-4656 Fax: 609 252-6000

John F. Bedard
Vice President
Worldwide Regulatory Affairs

Supplement to NDA 19-898
Pravachol® (pravastatin sodium) Tablets

November 27, 1995

Solomon Sobel, MD
Director, Division of Metabolism and
Endocrine Drug Products (HFD-510)
Center for Drug Evaluation and Research
Food and Drug Administration
Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857



Attention: Document Control Room (14B-19)

Dear Dr. Sobel :

Reference is made to our approved New Drug Application, NDA 19-898 for Pravachol® (pravastatin sodium) Tablets, and specifically to the manufacture of "reduced mass" tablets. Reduced mass tablets were the subject of supplement S-008, approved by FDA on February 9, 1994.

We are submitting this supplement in order to provide for the reprocessing of Pravachol® reduced mass tablets that do not meet requirements for physical attributes . Reprocessing entails

There are no changes in the specifications for Pravachol® Tablets.

Bristol-Myers Squibb Company certifies that a field copy of this supplemental application has been provided to the North Brunswick office (120 North Center Drive, North Brunswick, NJ 08902) of the Food and Drug Administration. We further certify that the field copy is a true copy of this supplemental application.

A Table of Contents for this submission follows this letter.

Should you have any questions concerning this supplement, please contact Mr. William J. Regan, Director - CMC for Marketed Products at (609) 252-4732.

REVIEWS COMPLETED

CSO ACTION:

☒ LETTER ☐ N.A.I.

Issued 4/4/96 4/12/96

CSO INITIALS DATE

Sincerely,

for

John F. Bedard
Vice President
Worldwide Regulatory Affairs

JFB/ccv/pak

DEPATRATMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

FORM APPROVED:OMB NO. 0910-0297
EXPIRATION DATE:NOVEMBER 30, 1996

USER FEE COVER SHEET

See Instructions on Reverse Before Completing This Form.

1.APPLICANT'S NAME AND ADDRESS

E.R. Squibb & Sons, Inc.
Bristol-Myers Squibb
P.O. Box 4000

2. USER FEE BILLING NAME, ADDRESS, AND CONTACT

Bristol-Myers Squibb
P.O. Box 4000
Princeton, NJ 08543-4000

Contact: Edward Joyce

3.TELEPHONE NUMBER (Include Area Code)

(609) 252-4000

4.PRODUCT NAME Pravachol® (pravastatin sodium) Tablets

5.DOES THIS APPLICATION CONTAIN CLINICAL DATA? ☐ YES X ☐ NO

IF YOUR RESPONSE IS "NO" AND THIS IS FOR A SUPPLEMENT, STOP HERE AND SIGN THIS FORM.

6.USERFEEI.D.NUMBER

7.LICENSE NUMBER/NDA N019898

8.IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCLUSIONS? IF SO, CHECK THE

☐ A LARGE VOLUME PARENTERAL DRUG PRODUCT APPROVED BEFORE 9/1/92

☐ AN INSULIN PRODUCT SUBMITTED UNDER 506

☐ THE APPLICATION IS SUBMITTED UNDER 505(B)(2) (See reverse before checking box.)

FOR BIOLOGICAL PRODUCTS ONLY

☐ WHOLE BLOOD OR BLOOD COMPONENTS FOR TRANSFUSION

☐ BOVINE BLOOD PRODUCT FOR TOPICAL APPLICATION LICENSED BEFORE 9/1/92

☐ A CRUDE ALLERGENIC EXTRACT PRODUCT

☐ AN "IN VITRO" DIAGNOSTIC BIOLOGIC PRODUCT LICENSED UNDER 351 OF THE PHS

9.a.HAS THIS APPLICATION QUALIFIED FOR A SMALL BUSINESS EXCEPTION? ☐ YES (See reverse if answered yes) ☐ NO

b.HAS A WAIVER OF APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION? ☐ YES (See reverse if answered ☐ NO

This completed form must be signed and accompany each new drug or biologic product, original or supplement.

SIGNATURE OF AUTHORIZED COMPANY REPRESENTATIVE	TITLE	DATE
John F. Bedard Grace D. Heckman for John Bedard	Vice Pres., Worldwide Reg. Affairs	11/27/95

FORM FDA 3397 (12/93)